Preparation of and clinical experiences with trien for the treatment of Wilson's disease in absolute intolerance of D-penicillamine.
作者信息
Harders H, Cohnen E
机构信息
Medizinische Abteilung, Allgemeines Krankenhaus Heidberg, Hamburg, W Germany.
出版信息
Proc R Soc Med. 1977;70 Suppl 3(Suppl 3):10-2. doi: 10.1177/00359157770700S306.
Abstract
摘要
相似文献
1
Preparation of and clinical experiences with trien for the treatment of Wilson's disease in absolute intolerance of D-penicillamine.曲恩汀在对D-青霉胺绝对不耐受的威尔逊病治疗中的制备及临床经验
Proc R Soc Med. 1977;70 Suppl 3(Suppl 3):10-2. doi: 10.1177/00359157770700S306.
2
Treatment of Wilson's disease with triethylene tetramine dihydrochloride. A case report.用二盐酸三乙烯四胺治疗威尔逊氏病。病例报告。
Dev Pharmacol Ther. 1980;1(5):318-24.
3
The management of Wilson's disease with trienthylene tetramine 2HC1 (Trien 2HC1).
Prog Clin Biol Res. 1979;34:271-80.
4
[Trientin in Wilson's disease. Therapeutic possibilities in patients who cannot tolerate penicillamine].
Tidsskr Nor Laegeforen. 1987 Aug 10;107(22):1770-1.
5
Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease.一名威尔逊病患者使用青霉胺治疗后肾病综合征的早期发作。
Am J Gastroenterol. 1998 Dec;93(12):2544-6. doi: 10.1111/j.1572-0241.1998.00715.x.
6
Treatment of Wilson's disease.威尔逊氏病的治疗
Semin Neurol. 1987 Jun;7(2):209-20. doi: 10.1055/s-2008-1041420.
7
Trientine for Wilson's disease.
Med Lett Drugs Ther. 1986 Jul 4;28(717):67.
8
The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease.曲恩汀在预防威尔逊病中中断青霉胺治疗的影响方面的应用。
N Engl J Med. 1987 Jul 23;317(4):209-13. doi: 10.1056/NEJM198707233170405.
9
The mechanisms of penicillamine, trientine, and zinc in the treatment of Wilson's disease.青霉胺、曲恩汀和锌治疗威尔逊病的机制。
Am J Gastroenterol. 1995 Jun;90(6):1026.
10
Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.在没有替代孤儿药（曲恩汀 - 锌）的情况下停用青霉胺：1例威尔逊病失代偿期肝硬化病例
J Clin Pharm Ther. 2007 Feb;32(1):101-7. doi: 10.1111/j.1365-2710.2007.00794.x.
引用本文的文献
1
Copper chelation by trientine dihydrochloride inhibits liver RFA-induced inflammatory responses in vivo.盐酸曲恩汀的铜螯合作用在体内可抑制肝脏射频消融诱导的炎症反应。
Inflamm Res. 2016 Dec;65(12):1009-1020. doi: 10.1007/s00011-016-0986-2. Epub 2016 Sep 9.
本文引用的文献
1
Wilson's disease: modification by L-DOPA.
Neuropadiatrie. 1973 Dec;4(4):453-7. doi: 10.1055/s-0028-1091761.
2
Triethylene tetramine dihydrochloride in Wilson's disease.
Lancet. 1970 Oct 10;2(7676):775. doi: 10.1016/s0140-6736(70)90251-5.
3
Management of penicillamine nephropathy in Wilson's disease: a new chelating agent.威尔逊病中青霉胺肾病的管理：一种新型螯合剂。
Lancet. 1969 Dec 27;2(7635):1401-2. doi: 10.1016/s0140-6736(69)90940-4.
4
Preparation of triethylenetetramine dihydrochloride for the treatment of Wilson's disease.用于治疗威尔逊氏病的二盐酸三乙烯四胺的制备。
Lancet. 1972 Apr 15;1(7755):853. doi: 10.1016/s0140-6736(72)90845-8.
5
Letter: Treatment of Wilson's disease.信件：威尔逊氏病的治疗
Br Med J. 1975 Dec 20;4(5998):706. doi: 10.1136/bmj.4.5998.706.
6
Letter: "Orphan-drug" development - whose responsibility?信函：“孤儿药”研发——谁之责任？
N Engl J Med. 1975 Jan 16;292(3):162. doi: 10.1056/nejm197501162920315.
7
Letter: More on "orphan" drugs.信函：关于“孤儿药”的更多内容。
N Engl J Med. 1975 Apr 10;292(15):813-4.
8
Letter: Treatment of Wilson's disease.信件：威尔逊氏病的治疗
Lancet. 1975 Dec 13;2(7946):1218. doi: 10.1016/s0140-6736(75)92721-x.
Zotero 插件